We are live on
!
Find out more
O
OrbiMed Portfolio holdings
AUM
$5.4B
1-Year Est. Return
163.13%
This Fund
S&P 500
This Quarter
Est. Return
+9.35%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$6.46B
AUM Growth
-$2.68M
(-0.04%)
Cap. Flow
-$148M
Cap. Flow
% of AUM
-2.29%
Top 10 Holdings %
Top 10 Hldgs %
39.36%
Holding
145
New
22
Increased
28
Reduced
21
Closed
17
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PRVL
Prevail Therapeutics Inc. Common Stock
PRVL
|
+$201M |
| 2 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$91.6M |
| 3 |
uniQure
QURE
|
+$57.2M |
| 4 |
Natera
NTRA
|
+$47.4M |
| 5 |
ATNX
Athenex, Inc. Common Stock
ATNX
|
+$47.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CMTA
Clementia Pharmaceuticals Inc.
CMTA
|
+$272M |
| 2 |
Guardant Health
GH
|
+$118M |
| 3 |
Viatris
VTRS
|
+$77.1M |
| 4 |
Teva Pharmaceuticals
TEVA
|
+$64M |
| 5 |
Humana
HUM
|
+$55.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 96.94% |
| 2 | Miscellaneous | 1.85% |
| 3 | Financials | 1.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HARP
51
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
| $31.8M | 0.49% |
244,641
| – | – |
|
52
CareDx
CDNA
$2.76B
| $29.8M | 0.46% |
827,600
| – | – |
|
|
OBSV
53
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $29.5M | 0.46% |
2,605,531
| – | – |
|
54
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$799B
| $29.3M | 0.45% |
100,000
+50,000
| +100% | +$14.4M |
|
|
CLVS
55
DELISTED
Clovis Oncology, Inc.
CLVS
| $28.4M | 0.44% |
1,913,234
-919,066
| -32% | -$16.6M |
|
56
Xtant Medical Holdings
XTNT
$45M
| $27.6M | 0.43% |
9,207,012
| – | – |
|
57
Gilead Sciences
GILD
$181B
| $27.1M | 0.42% |
401,600
-42,200
| -10% | -$2.78M |
|
|
58
Viatris
VTRS
$19.1B
| $26.1M | 0.41% |
1,373,305
-3,488,495
| -72% | -$77.1M |
|
59
Krystal Biotech
KRYS
$9.93B
| $25.9M | 0.4% |
642,006
+582,796
| +984% | +$19.1M |
|
|
ENDP
60
DELISTED
Endo International plc
ENDP
| $25.4M | 0.39% |
6,165,464
| – | – |
|
61
Corvus Pharmaceuticals
CRVS
$1.1B
| $24.6M | 0.38% |
6,565,685
+598,101
| +10% | +$2.34M |
|
|
ADVM
62
DELISTED
Adverum Biotechnologies
ADVM
| $23.3M | 0.36% |
196,020
+71,700
| +58% | +$5.93M |
|
63
Aurinia Pharmaceuticals
AUPH
$2.14B
| $23.2M | 0.36% |
3,531,002
+381,192
| +12% | +$2.43M |
|
64
CALL
Bristol-Myers Squibb
BMY
$130B
| $22.7M | 0.35% |
+500,000
| New | +$23.3M |
|
|
ONCE
65
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
| $22.5M | 0.35% |
+219,900
| New | +$23.7M |
|
66
Amgen
AMGN
$205B
| $22.5M | 0.35% |
122,100
| – | – |
|
|
GNFT
67
DELISTED
Genfit
GNFT
| $22.2M | 0.34% |
1,125,607
-104,707
| -9% | -$2.45M |
|
68
KALA BIO
KALA
$9.78M
| $22M | 0.34% |
1,381
| – | – |
|
69
Alcon
ALC
$32.8B
| $21.7M | 0.34% |
+351,380
| New | +$20.6M |
|
70
Biogen
BIIB
$32B
| $20.5M | 0.32% |
87,700
| – | – |
|
71
SI-BONE Inc
SIBN
$846M
| $20M | 0.31% |
985,368
| – | – |
|
72
Karyopharm Therapeutics
KPTI
$36.7M
| $18.9M | 0.29% |
+209,898
| New | +$16.9M |
|
|
SYBX
73
DELISTED
Synlogic
SYBX
| $18.5M | 0.29% |
135,333
| – | – |
|
74
CALL
Takeda Pharmaceutical
TAK
$59.8B
| $17.7M | 0.27% |
1,000,000
| – | – |
|
75
Rhythm Pharmaceuticals
RYTM
$6.72B
| $17.3M | 0.27% |
787,300
| – | – |
|
Similar funds
MYIA
SCM
BJL
BG
SNT
NL
RC
AC
OrbiMed's Q2 2019 Portfolio in Review
As of Q2 2019, OrbiMed held 145 positions worth $6.46B, down 0.04% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
OrbiMed's Q2 2019 filing shows 22 new, 28 increased, 21 reduced and 17 closed positions. Its largest new stake was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M. The largest sale was Clementia Pharmaceuticals Inc., an estimated $272M.
By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 98% a quarter earlier, followed by Miscellaneous and Financials.
- OrbiMed's largest Q2 2019 buy was Prevail Therapeutics Inc. Common Stock: 13,822,463 shares worth $182M.
- OrbiMed added most to Natera in Q2 2019, an estimated $47.4M increase.
- OrbiMed's biggest Q2 2019 reduction was Viatris, cutting an estimated $77.1M.
- OrbiMed fully exited Clementia Pharmaceuticals Inc. in Q2 2019, selling an estimated $272M.
- OrbiMed's ten largest holdings make up 39% of its $6.46B portfolio in Q2 2019.
- OrbiMed opened 22 new positions and closed 17 in Q2 2019.
- OrbiMed's portfolio value fell 0.04% quarter-over-quarter to $6.46B.
Based on OrbiMed's 13F filing for Q2 2019, filed 14 Aug 2019.